NU FH 2018 with chart reviewed family hx and NLP for FH sx |
Electronic Health Record-based Phenotyping Algorithm for Familial Hypercholesterolemia |
Northwestern University |
Case Only |
|
|
|
|
CHOP Part II- NONRESPONDERS |
Epilepsy/Antiepileptic drug response algorithm |
CHOP |
Case Only |
|
|
85% |
|
Asthma Algorithm Validation - CCHMC |
Asthma |
Cincinnati Children's Hospital Medical Center |
Case, Control |
|
|
96%, 82% |
|
Hypothyroidism Vanderbilt Implementation |
Hypothyroidism |
Vanderbilt University |
Case, Control |
|
|
98%, 100% |
|
CCHMC Type 2 DM |
Type 2 Diabetes - PRS Evaluation |
|
Case Only |
|
|
|
|
KPWA/UW (primary site) implementation |
Colorectal Cancer (CRC) |
Group Health and University of Washington |
Case, Control |
|
|
|
|
WBC Marshfield Implementation |
White Blood Cell Indices |
Marshfield Clinic Research Foundation |
Case Only |
|
|
90% |
88% |
Atopic dermatitis implementation - Marshfield |
Atopic Dermatitis Algorithm |
Marshfield Clinic Research Foundation |
Case, Control |
|
|
96%, 90% |
|
Demonstration Project RA Implementation |
Rheumatoid Arthritis - Demonstration Project |
Vanderbilt University |
Case, Control |
|
|
97%, 100% |
|
Pneumonia_data_4_7_institutes |
Pneumonia- VUMC eMERGE v5.1 |
|
Case Only |
|
|
|
|
Mayo SLE Implementation |
SLE (Systemic Lupus Erythematosus) using SLICC (Systemic Lupus Internation Collaborating Clinics) Criteria |
Mayo Clinic |
Case, Control |
0 |
0 |
|
|
CHOP Post-event Pain |
Post-event Pain algorithm |
CHOP |
Case, Control |
99 |
2 |
96% |
|
Early Childhood Obesity Implementation - Columbia |
Severe Early Childhood Obesity |
Columbia University |
Case, Control |
2 |
3 |
|
|
Validation of Asthma algorithm - Geisinger |
Asthma |
Geisinger |
Case, Control |
10 |
10 |
100%, 100% |
|
Marshfield C-diff implementation |
Clostridium Difficile Colitis |
Marshfield Clinic Research Foundation |
Case, Control |
21 |
10 |
100%, 100% |
|
Marshfield Zoster implementation |
Herpes Zoster |
Marshfield Clinic Research Foundation |
Case, Control |
10 |
10 |
100%, 100% |
|
Geisinger c.Diff eMERGE3 Implementation |
Clostridium Difficile Colitis |
Geisinger |
Case, Control |
20 |
20 |
100%, 100% |
100%, 100% |
Appendicitis Case 1, Control |
Appendicitis |
Cincinnati Children's Hospital Medical Center |
Case, Control |
15 |
20 |
93%, 100% |
|
Marshfield AAA implementation |
Abdominal Aortic Aneurysm ( AAA ) |
Marshfield Clinic Research Foundation |
Case, Control |
25 |
22 |
100%, 100% |
|
Marshfield Hearing loss validation |
Hearing Loss |
Marshfield Clinic Research Foundation |
Case, Control |
25 |
25 |
100%, 100% |
|
Group Health/University of Washington CRC Validation |
Colorectal Cancer (CRC) |
GH/UW |
Case, Control |
25 |
25 |
92%, 100% |
100%, 100% |
Statin and MACE Mount Sinai Implementation |
Statins and MACE |
Mount Sinai |
Case Only |
52 |
25 |
96%, 100% |
100%, 100% |
Implementation For Phase 3 eMERGE |
Electronic Health Record-based Phenotyping Algorithm for Familial Hypercholesterolemia |
Geisinger |
Case, Control |
25 |
25 |
100%, 96% |
|
Marshfield ACE-I cough implentation |
ACE Inhibitor (ACE-I) induced cough |
Marshfield Clinic Research Foundation |
Case, Control |
25 |
25 |
100%, 96% |
|
Geisinger Impl |
Colorectal Cancer (CRC) |
Geisinger |
Case, Control |
25 |
25 |
100%, 100% |
|